OrbiMed’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

OrbiMed’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-73,600	Closed	-$843K	–	140
2022 Q4	$843K	Buy	+73,600	New	+$606K	0.02%	112

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

OrbiMed's MACK Position: Q1 2023 in Review

OrbiMed sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2023, closing a stake of 73,600 shares — an estimated $843K sold.

OrbiMed first reported a position in MACK in Q4 2022 and held it in 1 quarter. The position peaked at $843K in Q4 2022. 50 funds tracked by Wall St. Rank hold MACK as of Q1 2023.

OrbiMed reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
OrbiMed sold 73,600 Merrimack Pharmaceuticals, Inc. shares in Q1 2023, an estimated $843K.
OrbiMed first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2022 and held it in 1 quarter.
OrbiMed's Merrimack Pharmaceuticals, Inc. position peaked at $843K in Q4 2022.
50 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2023.

Based on OrbiMed's 13F filing for Q1 2023, filed 15 May 2023.